By Josh Beckerman

Switzerland-based biotechnology company ADC Therapeutics SA has filed for an initial public offering.

ADC focuses on hematological malignancies and solid tumors.

The company plans to trade on the New York Stock Exchange under symbol ADCT. The filing lists an amount of $150 million.

Auven Therapeutics owns 42.7% stake of ADC. AstraZeneca PLC (AZN) owns 7.1%.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

September 06, 2019 20:11 ET (00:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.